Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma.
暂无分享,去创建一个
Li Zhang | Howard Colman | Dima Suki | Jan C Buckner | Susan M. Chang | K. Aldape | W. Yung | M. Prados | C. James | J. Buckner | H. Colman | K. Bhat | C. Pelloski | A. Heimberger | E. Sulman | K. Ballman | W. Yung | J. McDonald | S. Woo | F. Barker | D. Suki | C David James | Shiao Y Woo | Susan M Chang | Kenneth Aldape | Karla V Ballman | J Matthew McDonald | Fred G Barker | Erik P Sulman | E Lin | Michael D Prados | Christopher E Pelloski | Alfred F Furth | Krishna Bhat | W K Alfred Yung | Amy B Heimberger | A. Furth | Fredrick G. Barker | Li Zhang | E. Lin | J. Mcdonald | C. James
[1] A Guha,et al. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. , 1999, Neurosurgery.
[2] D. Nelson,et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. , 1993, Journal of the National Cancer Institute.
[3] W. Hall,et al. Identification of EGFRvIII-derived CTL Epitopes Restricted by HLA A0201 for Dendritic Cell Based Immunotherapy of Gliomas , 2005, Journal of Neuro-Oncology.
[4] Caterina Giannini,et al. Immunohistochemical Detection of EGFRvIII in High Malignancy Grade Astrocytomas and Evaluation of Prognostic Significance , 2004, Journal of neuropathology and experimental neurology.
[5] M. Prados,et al. Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors. , 1998, International journal of radiation oncology, biology, physics.
[6] R. B. Montgomery,et al. Constitutive Activation of Phosphatidylinositol 3-Kinase by a Naturally Occurring Mutant Epidermal Growth Factor Receptor* , 1998, The Journal of Biological Chemistry.
[7] A. Scott,et al. Treatment of Human Tumor Xenografts with Monoclonal Antibody 806 in Combination with a Prototypical Epidermal Growth Factor Receptor–Specific Antibody Generates Enhanced Antitumor Activity , 2005, Clinical Cancer Research.
[8] B. Scheithauer,et al. A phase III study of radiation therapy plus carmustine with or without recombinant interferon‐α in the treatment of patients with newly diagnosed high‐grade glioma , 2001 .
[9] T. Cascino,et al. Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade glioma. , 1998, International journal of radiation oncology, biology, physics.
[10] M. Berger,et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. , 2005, Journal of the National Cancer Institute.
[11] Siegfried Kropf,et al. Prognostic relevance of MAPK expression in glioblastoma multiforme. , 2003, International journal of oncology.
[12] Allan H Friedman,et al. Phase II trial of gefitinib in recurrent glioblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Alona Muzikansky,et al. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] K. Aldape,et al. YKL-40 Expression is Associated with Poorer Response to Radiation and Shorter Overall Survival in Glioblastoma , 2005, Clinical Cancer Research.
[15] David J. Yang,et al. Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients , 2005, Clinical Cancer Research.
[16] P. Black,et al. Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[17] T. Cascino,et al. Phase I evaluation of preirradiation chemotherapy with carmustine and cisplatin and accelerated radiation therapy in patients with high-grade gliomas. , 1999, Neurosurgery.
[18] H. Ling,et al. The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumour necrosis factor-alpha. , 2004, The Biochemical journal.
[19] Susan M. Chang,et al. Glioblastoma Patients Epidermal Growth Factor Receptor , and Survival in Analysis of Complex Relationships between Age , p 53 , Updated , 2001 .
[20] E. Shaw,et al. Reexamining the radiation therapy oncology group (RTOG) recursive partitioning analysis (RPA) for glioblastoma multiforme (GBM) patients , 2003 .
[21] A. Scott,et al. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. , 2001, Cancer research.
[22] Li Zhang,et al. Prognostic Associations of Activated Mitogen-Activated Protein Kinase and Akt Pathways in Glioblastoma , 2006, Clinical Cancer Research.
[23] R. Dinapoli,et al. Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma. , 1998, International journal of radiation oncology, biology, physics.
[24] I. Pastan,et al. Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[25] F. Harrell,et al. Regression modelling strategies for improved prognostic prediction. , 1984, Statistics in medicine.
[26] A. Friedman,et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[27] H Sakai,et al. A cross-validation of the European Organization for Research and Treatment of Cancer QLQ-C30 (EORTC QLQ-C30) for Japanese with lung cancer. , 1998, European journal of cancer.
[28] A. Pawson,et al. Proliferation of human malignant astrocytomas is dependent on Ras activation , 1997, Oncogene.
[29] W. Curran,et al. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. , 1998, International journal of radiation oncology, biology, physics.
[30] Kenji Tada,et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. , 2003, Cancer research.
[31] Koji Yoshimoto,et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.
[32] J. O'fallon,et al. Safety of thrice-daily hyperfractionated radiation and BCNU for high-grade gliomas. , 2002, International journal of radiation oncology, biology, physics.
[33] E. Bernhard,et al. Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin , 2004, Oncogene.
[34] H. Modjtahedi,et al. Targeting of cells expressing wild‐type EGFR and type‐III mutant EGFR (EGFRvIII) by anti‐EGFR MAb ICR62: A two‐pronged attack for tumour therapy , 2003, International journal of cancer.
[35] C. Conill,et al. Performance status assessment in cancer patients , 1990, Cancer.
[36] Paul S Mischel,et al. Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. , 2003, Cancer research.
[37] B. Scheithauer,et al. Randomized trial of radiation therapy (RT) plus dibromodulcitol (DBD) versus RT plus BCNU in high grade astrocytoma , 1997, Journal of Neuro-Oncology.
[38] Susan M. Chang,et al. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. , 2001, International journal of radiation oncology, biology, physics.
[39] K. Ichimura,et al. Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas , 2005, Journal of Molecular Medicine.
[40] D. W. Fry,et al. Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. , 2002, Seminars in oncology.
[41] H. Ling,et al. The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. , 2002, The Biochemical journal.